Targeting ischemic brain injury with intravenous immunoglobulin

Thiruma V. Arumugam, Pradeep K. Selvaraj, Trent M. Woodruff, Mark P. Mattson

Research output: Contribution to journalArticlepeer-review


Background: Intravenous immunoglobulin (IVIG) is a therapeutic modality approved for the treatment of autoimmune disorders. Objective: This review discusses how IVIG can prevent brain damage following ischemic stroke and discuss the potential mechanisms of action. Methods: Medline and the world wide web were searched and the relevant literature was classified under the following categories: IVIG, IVIG mechanism of action, and ischemic stroke injury mechanisms. Results/conclusion: Brain ischemia induces an inflammatory response that contributes to neuronal cell death. Because of its ability to block multiple molecular events, IVIG may have particularly strong neuroprotective action against ischemic brain injury. In light of the extensive clinical experience with IVIG for other indications, development of clinical trials to evaluate the use of IVIG in human stroke patients are warranted.

Original languageEnglish (US)
Pages (from-to)19-29
Number of pages11
JournalExpert Opinion on Therapeutic Targets
Issue number1
StatePublished - Jan 2008


  • Apoptosis
  • Cerebral ischemia
  • Complement
  • Intravenous immunoglobulin
  • Ischemic stroke
  • T lymphocytes

ASJC Scopus subject areas

  • Molecular Medicine
  • Biochemistry, Genetics and Molecular Biology(all)


Dive into the research topics of 'Targeting ischemic brain injury with intravenous immunoglobulin'. Together they form a unique fingerprint.

Cite this